Ontology highlight
ABSTRACT:
SUBMITTER: Capper D
PROVIDER: S-EPMC5454908 | biostudies-literature | 2017 May
REPOSITORIES: biostudies-literature
Capper David D von Deimling Andreas A Brandes Alba A AA Carpentier Antoine F AF Kesari Santosh S Sepulveda-Sanchez Juan M JM Wheeler Helen R HR Chinot Olivier O Cher Lawrence L Steinbach Joachim P JP Specenier Pol P Rodon Jordi J Cleverly Ann A Smith Claire C Gueorguieva Ivelina I Miles Colin C Guba Susan C SC Desaiah Durisala D Estrem Shawn T ST Lahn Michael M MM Wick Wolfgang W
International journal of molecular sciences 20170506 5
Galunisertib, a Transforming growth factor-βRI (TGF-βRI) kinase inhibitor, blocks TGF-β-mediated tumor growth in glioblastoma. In a three-arm study of galunisertib (300 mg/day) monotherapy (intermittent dosing; each cycle =14 days on/14 days off), lomustine monotherapy, and galunisertib plus lomustine therapy, baseline tumor tissue was evaluated to identify markers associated with tumor stage (e.g., histopathology, Ki67, glial fibrillary acidic protein) and TGF-β-related signaling (e.g., pSMAD2) ...[more]